BIOMARIN PHARMACEUTICAL INC Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 2.24 million shares for the 3-month period ending 2014-09-30, per its 10-Q filed 2015-11-02.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2015-11-02
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2014-09-30 was 2.24M shares.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2013-09-30 was 0.00 shares.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2012-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2011-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2012 was 0.00 shares.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2011 was 0.00 shares, a 100.00% decline from fiscal 2010.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2010 was 19.13M shares.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2009 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|
| 2014-09-30 | 2.24M shares 10-Q · filed 2015-11-02 | 0.00 shares 10-Q · filed 2014-10-28 | |
| 2013-09-30 | 0.00 shares 10-Q · filed 2014-10-28 | 0.00 shares 10-Q · filed 2014-10-28 | |
| 2012-12-31 | 0.00 shares 10-K · filed 2013-02-26 | ||
| 2012-03-31 | 0.00 shares 10-Q · filed 2012-04-30 | ||
| 2011-12-31 | 0.00 shares 10-K · filed 2013-02-26 | ||
| 2011-09-30 | 0.00 shares 10-Q · filed 2011-10-31 | 0.00 shares 10-Q · filed 2011-10-31 | |
| 2011-03-31 | 91.00K shares 10-Q · filed 2012-04-30 | ||
| 2010-12-31 | 19.13M shares 10-K · filed 2013-02-26 | ||
| 2010-09-30 | 26.34M shares 10-Q · filed 2011-10-31 | 26.34M shares 10-Q · filed 2011-10-31 | |
| 2009-12-31 | 0.00 shares 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |